Evidence map›Paper›PMID 38788532›Full record

ArticleDrug and alcohol dependence2024

Kratom addiction per DSM-5 SUD criteria, and kratom physical dependence: Insights from dosing amount versus frequency.

Jeffrey M Rogers, Stephanie T Weiss, David H Epstein, Oliver Grundmann, Katherine Hill, Kirsten E Smith

Abstract read
In one paragraph

Article in Drug and alcohol dependence, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Trial
  2. Interpol review of forensic drug chemistry, 2022-2025.Forensic science international. Synergy · 2026
    Review
  3. Indole Alkaloids as Biased Opioid Receptor Modulators.Pharmaceuticals (Basel, Switzerland) · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jeffrey M RogersSan Diego State University/University of California San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, United States.
Stephanie T WeissTranslational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, United States.
David H EpsteinReal-World Assessment, Prediction, and Treatment Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, United States.
Oliver GrundmannDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL, United States.
Katherine HillDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, United States.
Kirsten E SmithDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, United States. Electronic address: ksmit398@jh.edu.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Real-Time Assessment of Drug Use, Along with Mental States and EnvironmentsZIADA000499 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI EPSTEIN, DAVID · 2009 to 2025
$19.9M
Training in Research on Addictions in Interdisciplinary NeuroAIDS (TRAIN)T32DA031098 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jennifer E Iudicello, DAVID J MOORE · 2011 to 2026
$4.6M
Real-world momentary assessment of kratom use and laboratory-based observed cessation accompanied by product assays: Toward an interdisciplinary characterization of kratom use and pharmacologyR00DA055571 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SMITH, KIRSTEN · 2024 to 2025
$498k
Intramural NIH HHS ZIA DA000499NCATS NIH HHS UL1 TR001863NIDA NIH HHS K99 DA055571NIDA NIH HHS R00 DA055571NIDA NIH HHS T32 DA031098
6 · The paper itself

Abstract

backgroundKratom products are widely used in the United States, with inadequate understanding of how dosing amounts/frequencies relate to outcomes.

methodsBetween July-November 2022, we enrolled 395 active US adult kratom consumers into a remote study with a baseline survey. We examined self-reported typical dose amounts and frequencies across people and product types, and their associations with outcomes: multiple regression was used to examine whether amounts and frequencies (doses/day) were associated with acute effects, withdrawal symptoms, scores on the Subjective Opioid Withdrawal Scale (SOWS), and addiction (operationalized as DSM-5-based symptoms of kratom-use disorder, KUD).

resultsParticipants were 54.9% male, aged 38.1 on average, and 81.3% White. Mean length of kratom use was 5.7 years. Most (95.9%) reported regularly using whole-leaf kratom products; 16 (4.1%) reported regular extract use. SOWS scores were mild to moderate on average (13.5, SD 11.9). KUD symptom counts were mostly in the mild/moderate range (80.7%). Withdrawal and KUD symptoms were more closely associated with dose frequency than dose amount. Men reported more acute effects, withdrawal symptoms with cessation, and KUD symptoms than women.

conclusionsGreater dose amount and frequency were systematically related to the number of withdrawal symptoms upon cessation and to KUD symptoms; the relationship was stronger for dose frequency than amount. Men may have more acute effects and more withdrawal and KUD symptoms than women. Although kratom may be used nonproblematically by some consumers, physical dependence (tolerance, withdrawal, or use to avoid withdrawal) and KUD become more likely with increasing dose frequency.

Indexed as

Diagnostic and Statistical Manual of Mental DisordersMitragynaSubstance Withdrawal SyndromeAdultDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedSubstance-Related DisordersYoung AdultAddictionKratomSubstance use disorderToleranceWithdrawal

Identifiers

PMID38788532
PMCPMC11493341

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.